By Fineline Cube 
This week, China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) and iCarbonX entered into an innovative drug CRDMO service cooperation agreement and strategic investment agreement. This partnership aims to accelerate the development of iCarbonX’s pipeline, including peptide-drug conjugate (PDC) products and AI-based antimicrobial peptides.
Comprehensive Collaboration
Hybio will utilize its industry-leading peptide CRDMO platform to support iCarbonX’s projects throughout the entire process, from preclinical research to commercialization. This includes key stages such as process optimization of active pharmaceutical ingredients, formulation development, quality research, registration and application, and large-scale production.
Strategic Investment Focus
Hybio’s equity investment will specifically advance iCarbonX’s antimicrobial peptide programs, as well as the development of iCPDC-001. iCarbonX’s proprietary “Peptide Chip + AI” platform enables rapid candidate screening, enhancing the efficiency of drug discovery.
Previous Collaboration
The two companies previously established a joint development agreement for a GLP-1R/GIPR/GCGR tri-agonist in May of this year, with Hybio leading preclinical and pharmaceutical development. This latest agreement builds on a strategic cooperation framework established last year.-Fineline Info & Tech